Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateTimeSourceHeadlineSymbolCompany
01/02/202508:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
24/01/202509:41Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
22/01/202523:30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary AngioedemaNASDAQ:NTLAIntellia Therapeutics Inc
10/01/202523:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
10/01/202508:00GlobeNewswire Inc.Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)NASDAQ:NTLAIntellia Therapeutics Inc
08/01/202509:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
08/01/202509:22Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
08/01/202509:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
08/01/202509:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
08/01/202509:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
07/01/202508:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
06/01/202523:30GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
04/12/202408:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
25/11/202423:30GlobeNewswire Inc.Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with PolyneuropathyNASDAQ:NTLAIntellia Therapeutics Inc
18/11/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
17/11/202402:16GlobeNewswire Inc.Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) AmyloidosisNASDAQ:NTLAIntellia Therapeutics Inc
08/11/202408:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
07/11/202423:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
07/11/202423:30GlobeNewswire Inc.Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
06/11/202408:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
31/10/202422:30GlobeNewswire Inc.Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024NASDAQ:NTLAIntellia Therapeutics Inc
26/10/202407:59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
24/10/202423:01GlobeNewswire Inc.Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
10/10/202422:30GlobeNewswire Inc.Intellia Therapeutics Announces New Date for Upcoming Investor WebcastNASDAQ:NTLAIntellia Therapeutics Inc
07/10/202422:30GlobeNewswire Inc.Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
05/10/202407:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
04/10/202406:01GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
01/10/202421:30GlobeNewswire Inc.Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific SessionsNASDAQ:NTLAIntellia Therapeutics Inc
12/09/202421:30GlobeNewswire Inc.Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
04/09/202406:30GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA